365 related articles for article (PubMed ID: 10157738)
1. The American Society of Clinical Oncology guideline program.
Winn RF; Smith TF
Pharm Pract Manag Q; 1996 Apr; 16(1):31-8. PubMed ID: 10157738
[No Abstract] [Full Text] [Related]
2. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
Adams JR; Angelotta C; Bennett CL
J Clin Oncol; 2006 Jul; 24(19):2975-7. PubMed ID: 16682722
[No Abstract] [Full Text] [Related]
3. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
4. [Guidelines for prevention of febrile neutropenia].
Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
[TBL] [Abstract][Full Text] [Related]
5. [Place of CSF in pediatric oncology].
Hartmann O; Valteau-Couanet D
Pathol Biol (Paris); 1993 Jan; 41(1):52. PubMed ID: 7686289
[No Abstract] [Full Text] [Related]
6. [A general description of the clinical guideline for the management of febrile neutropenia].
Takamatsu Y
Gan To Kagaku Ryoho; 2013 Jun; 40(6):697-702. PubMed ID: 23863646
[TBL] [Abstract][Full Text] [Related]
7. [Growth factors in oncology: effectiveness and prospects].
Ottmann OG; Hoelzer D
Praxis (Bern 1994); 1998 Sep; 87(36):1153-9. PubMed ID: 9782744
[TBL] [Abstract][Full Text] [Related]
8. [Preventing and treating hematologic complications of anticancer chemotherapy: update on hematopoietic growth factors].
Spaëth D; Geoffrois L; Conroy T
Bull Cancer; 2000 Jan; 87(1):93-6. PubMed ID: 10673637
[No Abstract] [Full Text] [Related]
9. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
10. Growth factor frenzy.
Quesenberry PJ
Exp Hematol; 1993 Jul; 21(7):835-6. PubMed ID: 7686499
[No Abstract] [Full Text] [Related]
11. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
12. [Evidence-based management of neutropenia and fever].
Ishiguro H; Fung MC; Sakata T; Morizane T; Adachi S
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1365-71. PubMed ID: 14518423
[TBL] [Abstract][Full Text] [Related]
13. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
Klastersky J; Awada A; Aoun M; Paesmans M
Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2).
Lieschke GJ; Burgess AW
N Engl J Med; 1992 Jul; 327(2):99-106. PubMed ID: 1376442
[No Abstract] [Full Text] [Related]
15. [Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children].
Balwierz W; Moryl-Bujakowska A; Balwierz A; Pawińska K
Przegl Lek; 2006; 63(1):1-6. PubMed ID: 16892890
[TBL] [Abstract][Full Text] [Related]
16. Myeloid growth factors.
Crawford J; Armitage J; Balducci L; Bennett C; Blayney DW; Cataland SR; Dale DC; Demetri GD; Erba HP; Foran J; Freifeld AG; Goemann M; Heaney ML; Htoy S; Hudock S; Kloth DD; Kuter DJ; Lyman GH; Michaud LB; Miyata SC; Tallman MS; Vadhan-Raj S; Westervelt P; Wong MK;
J Natl Compr Canc Netw; 2009 Jan; 7(1):64-83. PubMed ID: 19176207
[No Abstract] [Full Text] [Related]
17. [Hematopoietic growth factors in oncology and hematology. Recommendations for more cost-efficient use].
Paul C; Hast R
Lakartidningen; 2000 Jun; 97(23):2862-6. PubMed ID: 10885223
[No Abstract] [Full Text] [Related]
18. Myeloid growth factors clinical practice guidelines in oncology.
Crawford J; Althaus B; Armitage J; Blayney DW; Cataland S; Dale DC; Demetri GD; Foran J; Heaney ML; Htoy S; Kloth DD; Lyman GH; Michaud L; Motl S; Vadhan-Raj S; Wong MK;
J Natl Compr Canc Netw; 2005 Jul; 3(4):540-55. PubMed ID: 16038645
[No Abstract] [Full Text] [Related]
19. Service plans and clinical interventions targeted by the oncology pharmacist.
Pon D
Pharm Pract Manag Q; 1996 Apr; 16(1):18-30. PubMed ID: 10157737
[TBL] [Abstract][Full Text] [Related]
20. Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia.
Freyer G; Ligneau B; Trillet-Lenoir V
Int J Antimicrob Agents; 1998 Apr; 10(1):3-9. PubMed ID: 9624538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
